Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.37 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 5/20 | 0.32 |
| ▸ | ACHE | P22303 | 5/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2054688 | 0.86 | BCHE (0.40) | BCHEACHE | |
| SCHEMBL4331680 | 0.76 | KIF11 (0.34) | KIF11PTPN5TSHRMAPK1S1PR1 | |
| SCHEMBL2145857 | 0.72 | PDE2A (0.34) | PTPN5TSHRMAPK1S1PR1PDE2A | |
| SCHEMBL19191095 | 0.72 | TACR1 (0.34) | KIF11TSHRMAPK1GPR84TACR1 | |
| SCHEMBL25415263 | 0.69 | TSHR (0.31) | TSHRMAPK1S1PR1 | |
| SCHEMBL7412520 | 0.69 | TSHR (0.31) | TSHRMAPK1GPR84S1PR1TACR1 | |
| SCHEMBL29659111 | 0.68 | KIF11 (0.36) | KIF11TSHRMAPK1 | |
| SCHEMBL16505901 | 0.67 | CFTR (0.49) | MAPK1TACR1 | |
| SCHEMBL2635687 | 0.67 | TACR1 (0.42) | TACR1 | |
| SCHEMBL30021484 | 0.67 | CFTR (0.49) | MAPK1TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963445-B2 | Chemical compounds | SYNGENTA LIMITED (GB) | 2018-05-08 | — | — | US | disclosed |
| US-20160159781-A1 | CHEMICAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159781-A1 | CHEMICAL COMPOUNDS | DDT, CBR3, CYP1B1 | KIF11 3376/4885PTPN5 997/4885BCHE 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.